Corcept Therapeutics growth playbook

Unpublish or redirect /about-3/, /publications-2/ and /ir-template/, and remove them from the sitemap. Set the homepage canonical to https://corcept.com/. Update the oncology and endocrinology pages to match the pipeline page's current status, linking to the prescribing information, and add a simple "Our medicines" panel on the homepage that links to the Products page and PI. Run all new wording through the Commercial Review Team. Then set a quarterly content check so status changes reach every page.

Physicians, patients, investors and job candidates who search Corcept, or ask an AI assistant, should get the current, reviewed picture rather than placeholder text or a 2024 description. It is a small, low-risk job with an outsized effect on first impressions.

[ ] No "(copy)", template or placeholder page in the sitemap
[ ] Homepage canonical is https://corcept.com/
[ ] Therapeutic area pages match pipeline status
[ ] Marketed medicines link to current PI
[ ] Every changed sentence approved by the Commercial Review Team
[ ] Dates on pages updated
[ ] Quarterly owner named

• Promotional content on a corporate page

  Every page, email and asset in this idea goes through Corcept's medical, legal and regulatory review (the Commercial Review Team) before use; nothing here is a claim about efficacy or safety.

• Old URLs still ranking

  Use 301 redirects to the live About and Publications pages.

• HiringSenior Manager, Digital & Omnichannel Marketing (Customer Experience), posted September 9, 2026: strategy and execution for "experience content and marketing automation including, customer relationship management, digital marketing tools, and website content management systems in support of Corcept's endocrinology products", for "patients, caregivers, and healthcare professionals"; coordinates "the Content Review Committee (CRT) ensuring timely review and approval of digital / non-personal promotions materials within legal, regulatory and compliance standards"; "ensure timely delivery in a launch setting"; experience "in AI/Machine Learning initiatives" preferred.Source
• Your websiteHomepage: "Explore the Possibilities of Cortisol Modulation", "more than 30 ongoing studies", and links to cortisol modulation, pipeline, stories and the team. It does not name either marketed medicine (Korlym, LIFYORLI). Its canonical tag points to https://corcept.com/home/, a second copy of the homepage, rather than to https://corcept.com/.Source
• Your websitePage sitemap, checked October 22, 2026: lists "/about-3/" (title "About (copy)") and "/pipeline-and-clinical-trials/publications-2/" (title "Publications (copy)"), each with a self-referencing canonical, and "/ir-template/", an investor relations template filled with Lorem ipsum placeholder text (20 placeholder paragraphs) and a fixed share price. None carries a noindex tag. Re-checked the same day with the same result.Source
• Your websiteThe oncology therapeutic area page (last modified March 2024 in the sitemap) describes how cortisol modulation "may" work in ovarian cancer and does not mention that LIFYORLI is approved; the endocrinology page (also March 2024) says relacorilant "is currently in Phase 3 clinical trials". The pipeline page shows ROSELLA/LIFYORLI as "APPROVED" and GRACE and GRADIENT as "FILED".Source
• FDAFDA, March 2026: approval of relacorilant (LIFYORLI) with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic regimens, at least one including bevacizumab.Source
• Your websiteProducts page: LIFYORLI and Korlym prescribing information, links to lifyorli.com and korlym.com, state price disclosures, the adverse event line and Medical Information Request. Only Korlym has a link to "Access & Financial Support" and the "Patient Advocate Program", and a Spanish Medication Guide ("Guía del medicamento de Korlym").Source

Fix the list template so only title, authors, year and venue show, then add filters for study, therapeutic area, year and congress, keeping the investigational-use note at the top. Have Medical Affairs confirm the library stays scientific and non-promotional.

Thought leaders and medical teams use this library; a clean, filterable list makes the science easy to find and removes an obvious template error.

• Library seen as promotional

  Keep it under Medical Affairs ownership. Every page, email and asset in this idea goes through Corcept's medical, legal and regulatory review (the Commercial Review Team) before use; nothing here is a claim about efficacy or safety.

• Your websitePublications library: 191 entries (journal papers and congress presentations, many from 2026 on GRACE, ROSELLA, MOMENTUM and CATALYST), with the note "may include information regarding investigational products or uses". Each entry in the list also prints raw template data (logo file paths, edit timestamps and other internal fields) as visible text. There is no filter by study, therapeutic area or congress.Source
• HiringThought Leader Liaisons (Mid-Atlantic, New England) "advance understanding of hypercortisolism across multiple specialties": "endocrinologists, diabetologists, cardiologists, nephrologists, radiologists, endocrine surgeons"; they capture insights "using approved systems such as SteepRock OLMS". Clinical Sales Specialists are being hired in at least ten US territories, including Birmingham, Montgomery, Pittsburgh North and Hartford.Source
• HiringSenior Manager, Marketing (Peer to Peer Education), posted October 1, 2026, within Thought Leader Programming: builds "slide decks, roundtable guides, patient cases", partners "with faculty and KOLs", supports "Speaker Bureau" and conference teams, and manages content "through the promotional review and approval process, including Veeva submissions, Commercial Review Team (CRT) review, timelines, approvals, reapprovals, and expirations".Source

Compress and resize hero images to modern formats, set long cache lifetimes on static files, reserve space for the consent banner and hero to stop layout shift, and recheck in the Chrome UX Report after a month.

Physicians often look things up on phones between patients; a fast site supports every other digital program.

• Theme changes break layout

  Test on a staging copy first.

• Google PageSpeedHomepage, mobile lab test: performance 48, layout shift 0.188, largest paint 44.6 s (the consent banner), with estimated savings of 10 MB from cache lifetimes and 4 MB from image delivery. Real visitors (Chrome UX Report): homepage LCP 3.0 s, above Google's 2.5 s "good" line; site-wide LCP 2.5 s and 20% slower than before. Interaction is fine (INP 94 ms).Source

Add the approved LIFYORLI access and support link (or the lifyorli.com support page) beside its PI, with the support phone number and hours, and check both products show the same kinds of help. Run the wording through the Commercial Review Team.

Access help is the most practical thing a prescriber's office needs, and parity between the two products removes a dead end.

• Inconsistent support descriptions

  Every page, email and asset in this idea goes through Corcept's medical, legal and regulatory review (the Commercial Review Team) before use; nothing here is a claim about efficacy or safety.

• Your websiteProducts page: LIFYORLI and Korlym prescribing information, links to lifyorli.com and korlym.com, state price disclosures, the adverse event line and Medical Information Request. Only Korlym has a link to "Access & Financial Support" and the "Patient Advocate Program", and a Spanish Medication Guide ("Guía del medicamento de Korlym").Source
• HiringSenior Director, National Field Access, Endocrinology: "Define and drive national field access strategy for Korlym and Relacorilant", working with "Patient Services (HUB)", specialty pharmacy partners and Marketing on "access tools, and reimbursement support materials". Field Reimbursement Managers are open in Florida Miami/PR, Ohio and Washington D.C.Source
• HiringSenior Manager, Oncology Commercial Learning and Development (posted October 7, 2026): onboarding and field training "supporting the LIFYORLI Sales team", managing the LMS and "Veeva workflows", and "consultative support to ex-U.S. teams, sharing U.S. launch training experience". Europe: a Director, Sales DACH ("as Corcept launches and grows its oncology portfolio in Europe"), an Associate Director, Europe Business Analytics & Insights (Munich), Europe Sales Training & Operations and Oncology Distribution, Europe (Amsterdam).Source

Tag stories by area (endocrinology, oncology, people and science), add a short related-resources block on each (disease awareness pages, advocacy organizations, Medical Information Request), and keep each patient's consent and the review record on file.

Stories are what people share; a clear next step turns a moving read into awareness and support.

• Implied product claims in patient stories

  Every page, email and asset in this idea goes through Corcept's medical, legal and regulatory review (the Commercial Review Team) before use; nothing here is a claim about efficacy or safety.

• Your websiteStories page: 4 pages of articles, including patient journeys with Cushing syndrome and ovarian cancer, a "Founding Corcept" video and heritage-month profiles of scientists. About page: Korlym approved in 2012 as "the first approved treatment for hypercortisolism (Cushing syndrome)", "750+ employees", "1000+ novel molecules".Source
• Your websiteProducts page: LIFYORLI and Korlym prescribing information, links to lifyorli.com and korlym.com, state price disclosures, the adverse event line and Medical Information Request. Only Korlym has a link to "Access & Financial Support" and the "Patient Advocate Program", and a Spanish Medication Guide ("Guía del medicamento de Korlym").Source

Produce short, reviewed videos from existing stories and scientist profiles, post them on LinkedIn and YouTube with captions, and link back to the story pages.

Video reaches people who will not read a long article, and the content already exists.

• Comments with adverse event reports

  Set up monitoring and pharmacovigilance routing before posting.

• Social profilesCorcept's YouTube channel has 17 videos and 91 subscribers (about 3,500 total views). The investor site ir.corcept.com returned "Access Denied" to a standard automated request on October 22, 2026, while corcept.com served normally.Source
• Your websiteStories page: 4 pages of articles, including patient journeys with Cushing syndrome and ovarian cancer, a "Founding Corcept" video and heritage-month profiles of scientists. About page: Korlym approved in 2012 as "the first approved treatment for hypercortisolism (Cushing syndrome)", "750+ employees", "1000+ novel molecules".Source

With Medical Affairs, build an unbranded disease-awareness program for each specialty: a short web hub on when to consider screening per published guidelines, congress materials and email journeys to opted-in HCPs. Measure engagement, not prescriptions.

Awareness in adjacent specialties is where undiagnosed patients are, and unbranded education is the appropriate channel.

• Line between awareness and promotion

  Every page, email and asset in this idea goes through Corcept's medical, legal and regulatory review (the Commercial Review Team) before use; nothing here is a claim about efficacy or safety.

• HiringThought Leader Liaisons (Mid-Atlantic, New England) "advance understanding of hypercortisolism across multiple specialties": "endocrinologists, diabetologists, cardiologists, nephrologists, radiologists, endocrine surgeons"; they capture insights "using approved systems such as SteepRock OLMS". Clinical Sales Specialists are being hired in at least ten US territories, including Birmingham, Montgomery, Pittsburgh North and Hartford.Source
• Your websitePublications library: 191 entries (journal papers and congress presentations, many from 2026 on GRACE, ROSELLA, MOMENTUM and CATALYST), with the note "may include information regarding investigational products or uses". Each entry in the list also prints raw template data (logo file paths, edit timestamps and other internal fields) as visible text. There is no filter by study, therapeutic area or congress.Source
• HiringSenior Manager, Digital & Omnichannel Marketing (Customer Experience), posted September 9, 2026: strategy and execution for "experience content and marketing automation including, customer relationship management, digital marketing tools, and website content management systems in support of Corcept's endocrinology products", for "patients, caregivers, and healthcare professionals"; coordinates "the Content Review Committee (CRT) ensuring timely review and approval of digital / non-personal promotions materials within legal, regulatory and compliance standards"; "ensure timely delivery in a launch setting"; experience "in AI/Machine Learning initiatives" preferred.Source
• HiringDirector, Key Account Managers: the KAM team focuses on "institutional partnerships, disease awareness, screening pathway development, EMR decision-support initiatives"; leads "national strategy to influence system workflows, including screening pathways, EMR flags, order sets, decision-support tools, and referral coordination" across "IDNs, ACOs, academic centers, and multi-hospital systems".Source

Build approved modules (disease state, guideline summaries, case templates) that speakers combine within set rules, track expiry dates centrally, and review only new modules. Give speakers a library in one place.

Faster review means more programs on current content, and fewer expired materials in the field.

• Modules used out of context

  Every page, email and asset in this idea goes through Corcept's medical, legal and regulatory review (the Commercial Review Team) before use; nothing here is a claim about efficacy or safety.

• HiringSenior Manager, Marketing (Peer to Peer Education), posted October 1, 2026, within Thought Leader Programming: builds "slide decks, roundtable guides, patient cases", partners "with faculty and KOLs", supports "Speaker Bureau" and conference teams, and manages content "through the promotional review and approval process, including Veeva submissions, Commercial Review Team (CRT) review, timelines, approvals, reapprovals, and expirations".Source
• HiringSenior Manager, Digital & Omnichannel Marketing (Customer Experience), posted September 9, 2026: strategy and execution for "experience content and marketing automation including, customer relationship management, digital marketing tools, and website content management systems in support of Corcept's endocrinology products", for "patients, caregivers, and healthcare professionals"; coordinates "the Content Review Committee (CRT) ensuring timely review and approval of digital / non-personal promotions materials within legal, regulatory and compliance standards"; "ensure timely delivery in a launch setting"; experience "in AI/Machine Learning initiatives" preferred.Source

Build triggered journeys in the CRM: after a visit on access, send the approved reimbursement resource; after a disease-state discussion, the unbranded hub. Respect consent and frequency limits and report engagement to the field.

Consistent follow-up keeps the conversation going between visits without extra field time.

• Over-messaging

  Frequency caps per HCP.

• Content approvals

  Every page, email and asset in this idea goes through Corcept's medical, legal and regulatory review (the Commercial Review Team) before use; nothing here is a claim about efficacy or safety.

• HiringSenior Manager, Digital & Omnichannel Marketing (Customer Experience), posted September 9, 2026: strategy and execution for "experience content and marketing automation including, customer relationship management, digital marketing tools, and website content management systems in support of Corcept's endocrinology products", for "patients, caregivers, and healthcare professionals"; coordinates "the Content Review Committee (CRT) ensuring timely review and approval of digital / non-personal promotions materials within legal, regulatory and compliance standards"; "ensure timely delivery in a launch setting"; experience "in AI/Machine Learning initiatives" preferred.Source
• HiringSenior Director, National Field Access, Endocrinology: "Define and drive national field access strategy for Korlym and Relacorilant", working with "Patient Services (HUB)", specialty pharmacy partners and Marketing on "access tools, and reimbursement support materials". Field Reimbursement Managers are open in Florida Miami/PR, Ohio and Washington D.C.Source
• HiringThought Leader Liaisons (Mid-Atlantic, New England) "advance understanding of hypercortisolism across multiple specialties": "endocrinologists, diabetologists, cardiologists, nephrologists, radiologists, endocrine surgeons"; they capture insights "using approved systems such as SteepRock OLMS". Clinical Sales Specialists are being hired in at least ten US territories, including Birmingham, Montgomery, Pittsburgh North and Hartford.Source

With Medical Affairs, develop a non-promotional toolkit health systems can adapt: guideline references, example pathway diagrams and quality-improvement measures. Offer it through KAMs and route research questions to Medical.

Institution-level change reaches many patients at once and lasts beyond any single visit.

• Perceived as steering

  Keep it guideline-based and owned by the system. Every page, email and asset in this idea goes through Corcept's medical, legal and regulatory review (the Commercial Review Team) before use; nothing here is a claim about efficacy or safety.

• HiringDirector, Key Account Managers: the KAM team focuses on "institutional partnerships, disease awareness, screening pathway development, EMR decision-support initiatives"; leads "national strategy to influence system workflows, including screening pathways, EMR flags, order sets, decision-support tools, and referral coordination" across "IDNs, ACOs, academic centers, and multi-hospital systems".Source
• Your websitePublications library: 191 entries (journal papers and congress presentations, many from 2026 on GRACE, ROSELLA, MOMENTUM and CATALYST), with the note "may include information regarding investigational products or uses". Each entry in the list also prints raw template data (logo file paths, edit timestamps and other internal fields) as visible text. There is no filter by study, therapeutic area or congress.Source
• HiringThought Leader Liaisons (Mid-Atlantic, New England) "advance understanding of hypercortisolism across multiple specialties": "endocrinologists, diabetologists, cardiologists, nephrologists, radiologists, endocrine surgeons"; they capture insights "using approved systems such as SteepRock OLMS". Clinical Sales Specialists are being hired in at least ten US territories, including Birmingham, Montgomery, Pittsburgh North and Hartford.Source

Publish an approved office hub: benefit verification steps, prior authorization checklists, specialty pharmacy contacts and HUB enrollment, with a request-a-visit form for FRMs.

Removing access friction is where many therapy starts are lost; self-serve answers scale the FRM team.

• Payer rules change

  Monthly review owner.

• HiringSenior Director, National Field Access, Endocrinology: "Define and drive national field access strategy for Korlym and Relacorilant", working with "Patient Services (HUB)", specialty pharmacy partners and Marketing on "access tools, and reimbursement support materials". Field Reimbursement Managers are open in Florida Miami/PR, Ohio and Washington D.C.Source
• Your websiteProducts page: LIFYORLI and Korlym prescribing information, links to lifyorli.com and korlym.com, state price disclosures, the adverse event line and Medical Information Request. Only Korlym has a link to "Access & Financial Support" and the "Patient Advocate Program", and a Spanish Medication Guide ("Guía del medicamento de Korlym").Source
• HiringSenior Manager, Digital & Omnichannel Marketing (Customer Experience), posted September 9, 2026: strategy and execution for "experience content and marketing automation including, customer relationship management, digital marketing tools, and website content management systems in support of Corcept's endocrinology products", for "patients, caregivers, and healthcare professionals"; coordinates "the Content Review Committee (CRT) ensuring timely review and approval of digital / non-personal promotions materials within legal, regulatory and compliance standards"; "ensure timely delivery in a launch setting"; experience "in AI/Machine Learning initiatives" preferred.Source

Break approved training into short modules in the LMS, add certification checks, give managers a ramp dashboard, and package the same modules for European teams with local review.

Faster, consistent ramp means compliant conversations sooner, in the US and Europe.

• Outdated modules

  Expiry tracking per module.

• HiringSenior Manager, Oncology Commercial Learning and Development (posted October 7, 2026): onboarding and field training "supporting the LIFYORLI Sales team", managing the LMS and "Veeva workflows", and "consultative support to ex-U.S. teams, sharing U.S. launch training experience". Europe: a Director, Sales DACH ("as Corcept launches and grows its oncology portfolio in Europe"), an Associate Director, Europe Business Analytics & Insights (Munich), Europe Sales Training & Operations and Oncology Distribution, Europe (Amsterdam).Source

Add German and Dutch corporate pages (about, science, contact, medical information and careers), following each country's rules on prescription medicine communication, and link the European careers openings.

Local corporate presence supports recruitment, partnerships and trust during a launch.

• Different national rules

  Local legal sign-off per country.

• HiringSenior Manager, Oncology Commercial Learning and Development (posted October 7, 2026): onboarding and field training "supporting the LIFYORLI Sales team", managing the LMS and "Veeva workflows", and "consultative support to ex-U.S. teams, sharing U.S. launch training experience". Europe: a Director, Sales DACH ("as Corcept launches and grows its oncology portfolio in Europe"), an Associate Director, Europe Business Analytics & Insights (Munich), Europe Sales Training & Operations and Oncology Distribution, Europe (Amsterdam).Source
• Your websiteHomepage: "Explore the Possibilities of Cortisol Modulation", "more than 30 ongoing studies", and links to cortisol modulation, pipeline, stories and the team. It does not name either marketed medicine (Korlym, LIFYORLI). Its canonical tag points to https://corcept.com/home/, a second copy of the homepage, rather than to https://corcept.com/.Source

Keep a library of approved statements, safety information blocks and visual components with their approval references, so new assets reuse them and reviewers check only what is new.

Shorter review cycles let a small digital team ship more, and reduce errors.

• Statements used out of context

  Every page, email and asset in this idea goes through Corcept's medical, legal and regulatory review (the Commercial Review Team) before use; nothing here is a claim about efficacy or safety.

• HiringSenior Manager, Digital & Omnichannel Marketing (Customer Experience), posted September 9, 2026: strategy and execution for "experience content and marketing automation including, customer relationship management, digital marketing tools, and website content management systems in support of Corcept's endocrinology products", for "patients, caregivers, and healthcare professionals"; coordinates "the Content Review Committee (CRT) ensuring timely review and approval of digital / non-personal promotions materials within legal, regulatory and compliance standards"; "ensure timely delivery in a launch setting"; experience "in AI/Machine Learning initiatives" preferred.Source
• HiringSenior Manager, Marketing (Peer to Peer Education), posted October 1, 2026, within Thought Leader Programming: builds "slide decks, roundtable guides, patient cases", partners "with faculty and KOLs", supports "Speaker Bureau" and conference teams, and manages content "through the promotional review and approval process, including Veeva submissions, Commercial Review Team (CRT) review, timelines, approvals, reapprovals, and expirations".Source

Each quarter, review insight themes with marketing and Medical Affairs and agree the top five content gaps, with owners and review timelines.

Content that answers real questions in the field gets used.

• Medical insights used promotionally

  Keep medical and commercial use separate. Every page, email and asset in this idea goes through Corcept's medical, legal and regulatory review (the Commercial Review Team) before use; nothing here is a claim about efficacy or safety.

• HiringThought Leader Liaisons (Mid-Atlantic, New England) "advance understanding of hypercortisolism across multiple specialties": "endocrinologists, diabetologists, cardiologists, nephrologists, radiologists, endocrine surgeons"; they capture insights "using approved systems such as SteepRock OLMS". Clinical Sales Specialists are being hired in at least ten US territories, including Birmingham, Montgomery, Pittsburgh North and Hartford.Source
• HiringDirector, Key Account Managers: the KAM team focuses on "institutional partnerships, disease awareness, screening pathway development, EMR decision-support initiatives"; leads "national strategy to influence system workflows, including screening pathways, EMR flags, order sets, decision-support tools, and referral coordination" across "IDNs, ACOs, academic centers, and multi-hospital systems".Source
• HiringSenior Manager, Pipeline & Portfolio Market Planning (posted September 30, 2026): oncology "indication selection and sequencing, patient journey and treatment paradigm analyses", competitive intelligence and forecasts. Manager, Internal Events and Community (posted October 16, 2026): employee events including "Fundraising events, walks, and runs" and "Volunteer programs".Source
• HiringSenior Manager, Marketing (Peer to Peer Education), posted October 1, 2026, within Thought Leader Programming: builds "slide decks, roundtable guides, patient cases", partners "with faculty and KOLs", supports "Speaker Bureau" and conference teams, and manages content "through the promotional review and approval process, including Veeva submissions, Commercial Review Team (CRT) review, timelines, approvals, reapprovals, and expirations".Source

Use consented engagement data to suggest the next channel and approved asset for each HCP (rep visit, email, webinar), with every asset pre-approved and humans deciding. Start with one region.

Better timing and channel choice raise engagement without more content.

• Automated promotion

  Only pre-approved assets; humans decide. Every page, email and asset in this idea goes through Corcept's medical, legal and regulatory review (the Commercial Review Team) before use; nothing here is a claim about efficacy or safety.

• HiringSenior Manager, Digital & Omnichannel Marketing (Customer Experience), posted September 9, 2026: strategy and execution for "experience content and marketing automation including, customer relationship management, digital marketing tools, and website content management systems in support of Corcept's endocrinology products", for "patients, caregivers, and healthcare professionals"; coordinates "the Content Review Committee (CRT) ensuring timely review and approval of digital / non-personal promotions materials within legal, regulatory and compliance standards"; "ensure timely delivery in a launch setting"; experience "in AI/Machine Learning initiatives" preferred.Source
• HiringThought Leader Liaisons (Mid-Atlantic, New England) "advance understanding of hypercortisolism across multiple specialties": "endocrinologists, diabetologists, cardiologists, nephrologists, radiologists, endocrine surgeons"; they capture insights "using approved systems such as SteepRock OLMS". Clinical Sales Specialists are being hired in at least ten US territories, including Birmingham, Montgomery, Pittsburgh North and Hartford.Source

Add a trial finder: each study with status, eligibility summary and link to ClinicalTrials.gov, searchable by condition and location, plus a referral contact for physicians.

Enrollment speed drives the pipeline, and a clear finder helps physicians refer.

• Investigational products promoted

  Describe studies only, link to registries. Every page, email and asset in this idea goes through Corcept's medical, legal and regulatory review (the Commercial Review Team) before use; nothing here is a claim about efficacy or safety.

• Your websiteThe oncology therapeutic area page (last modified March 2024 in the sitemap) describes how cortisol modulation "may" work in ovarian cancer and does not mention that LIFYORLI is approved; the endocrinology page (also March 2024) says relacorilant "is currently in Phase 3 clinical trials". The pipeline page shows ROSELLA/LIFYORLI as "APPROVED" and GRACE and GRADIENT as "FILED".Source
• Your websiteHomepage: "Explore the Possibilities of Cortisol Modulation", "more than 30 ongoing studies", and links to cortisol modulation, pipeline, stories and the team. It does not name either marketed medicine (Korlym, LIFYORLI). Its canonical tag points to https://corcept.com/home/, a second copy of the homepage, rather than to https://corcept.com/.Source
• Your websiteStories page: 4 pages of articles, including patient journeys with Cushing syndrome and ovarian cancer, a "Founding Corcept" video and heritage-month profiles of scientists. About page: Korlym approved in 2012 as "the first approved treatment for hypercortisolism (Cushing syndrome)", "750+ employees", "1000+ novel molecules".Source

Build an educational hub on cortisol biology and the glucocorticoid receptor, with explainer videos, scientist interviews and references, separated from product content and reviewed.

A trusted science source supports recruitment, partnerships and investor understanding at once.

• Science content read as promotion

  Every page, email and asset in this idea goes through Corcept's medical, legal and regulatory review (the Commercial Review Team) before use; nothing here is a claim about efficacy or safety.

• Your websiteStories page: 4 pages of articles, including patient journeys with Cushing syndrome and ovarian cancer, a "Founding Corcept" video and heritage-month profiles of scientists. About page: Korlym approved in 2012 as "the first approved treatment for hypercortisolism (Cushing syndrome)", "750+ employees", "1000+ novel molecules".Source
• Your websitePublications library: 191 entries (journal papers and congress presentations, many from 2026 on GRACE, ROSELLA, MOMENTUM and CATALYST), with the note "may include information regarding investigational products or uses". Each entry in the list also prints raw template data (logo file paths, edit timestamps and other internal fields) as visible text. There is no filter by study, therapeutic area or congress.Source
• Your websiteHomepage: "Explore the Possibilities of Cortisol Modulation", "more than 30 ongoing studies", and links to cortisol modulation, pipeline, stories and the team. It does not name either marketed medicine (Korlym, LIFYORLI). Its canonical tag points to https://corcept.com/home/, a second copy of the homepage, rather than to https://corcept.com/.Source

Ask the IR site provider to confirm which crawlers are allowed, test with Google Search Console and common AI crawlers, and mirror key press releases on corcept.com if needed.

Investors and journalists increasingly ask AI assistants; missing releases mean outdated answers.

• Bot protection weakened

  Allow only named crawlers.

• Social profilesCorcept's YouTube channel has 17 videos and 91 subscribers (about 3,500 total views). The investor site ir.corcept.com returned "Access Denied" to a standard automated request on October 22, 2026, while corcept.com served normally.Source
• Your websiteHomepage: "Explore the Possibilities of Cortisol Modulation", "more than 30 ongoing studies", and links to cortisol modulation, pipeline, stories and the team. It does not name either marketed medicine (Korlym, LIFYORLI). Its canonical tag points to https://corcept.com/home/, a second copy of the homepage, rather than to https://corcept.com/.Source

Join or sponsor advocacy walks in both areas, with employee teams, approved awareness materials and coverage on Stories and LinkedIn.

It builds culture and awareness together and connects Corcept with patient communities.

• Sponsorship rules

  Compliance sign-off for each event.

• HiringSenior Manager, Pipeline & Portfolio Market Planning (posted September 30, 2026): oncology "indication selection and sequencing, patient journey and treatment paradigm analyses", competitive intelligence and forecasts. Manager, Internal Events and Community (posted October 16, 2026): employee events including "Fundraising events, walks, and runs" and "Volunteer programs".Source
• Your websiteStories page: 4 pages of articles, including patient journeys with Cushing syndrome and ovarian cancer, a "Founding Corcept" video and heritage-month profiles of scientists. About page: Korlym approved in 2012 as "the first approved treatment for hypercortisolism (Cushing syndrome)", "750+ employees", "1000+ novel molecules".Source

With Medical Affairs and Patient Services, identify which approved patient resources (support program information, disease awareness pages) to translate and publish in Spanish.

Language access helps patients start and stay on therapy and supports field teams in Spanish-speaking regions.

• Translation accuracy

  Native medical reviewers. Every page, email and asset in this idea goes through Corcept's medical, legal and regulatory review (the Commercial Review Team) before use; nothing here is a claim about efficacy or safety.

• Your websiteProducts page: LIFYORLI and Korlym prescribing information, links to lifyorli.com and korlym.com, state price disclosures, the adverse event line and Medical Information Request. Only Korlym has a link to "Access & Financial Support" and the "Patient Advocate Program", and a Spanish Medication Guide ("Guía del medicamento de Korlym").Source
• HiringSenior Director, National Field Access, Endocrinology: "Define and drive national field access strategy for Korlym and Relacorilant", working with "Patient Services (HUB)", specialty pharmacy partners and Marketing on "access tools, and reimbursement support materials". Field Reimbursement Managers are open in Florida Miami/PR, Ohio and Washington D.C.Source